Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here is the video where Handley talks about it:
https://www.facebook.com/607135342719499/posts/d41d8cd9/1137541916345503/
Didn’t Handley and Lake Shore Recycling analyze and evaluate the digester in South Korea with Ecolocap for about two years prior to showcasing the machine with Ecolocap at their Illinois location back in Fall 2017?
VGCP had issued an interesting S-8 today.
No wonder Dr. Dalton is placing these companies under the Univec Conglomerate. He is already the CEO, Director, President, and Chairman of all of them. It just makes sense.
https://quotes.wsj.com/CA/XTSX/REW/company-people/executive-profile/68198
“David L. Dalton
Director, Rewardstream Solutions, Inc.
David L. Dalton is a businessperson who has been at the head of 5 different companies and presently occupies the position of Chairman, President & Chief Executive Officer for Univec, Inc. and Chairman, President & Chief Executive Officer for Physician & Pharmaceutical Services, Inc. (a subsidiary of Univec, Inc.), Chairman. President & Chief Executive Officer at Pharmacy Services, Inc. and Chairman, President & Chief Executive Officer at Health Resources, Inc. Dr. Dalton is also on the board of Rewardstream Solutions, Inc.
In the past David L. Dalton was Chairman, President & Chief Executive Officer of Health Resources, Inc.
He received an undergraduate degree from West Virginia University.”
$$$ UNVC $$$
Per Dr. David Dalton:
https://www.pressreader.com/canada/stockwatch-daily/20190506/281835760128384
“We seek Safe Harbor.”
Geoffery Balderson, David Dalton, Patrick Clarence Morris
$$$ UNVC $$$
Per the Wall Street Journal:
https://quotes.wsj.com/CA/XTSX/REW/company-people/executive-profile/68198
“David L. Dalton
Director, Rewardstream Solutions, Inc.
David L. Dalton is a businessperson who has been at the head of 5 different companies and presently occupies the position of Chairman, President & Chief Executive Officer for Univec, Inc. and Chairman, President & Chief Executive Officer for Physician & Pharmaceutical Services, Inc. (a subsidiary of Univec, Inc.), Chairman. President & Chief Executive Officer at Pharmacy Services, Inc. and Chairman, President & Chief Executive Officer at Health Resources, Inc. Dr. Dalton is also on the board of Rewardstream Solutions, Inc.
In the past David L. Dalton was Chairman, President & Chief Executive Officer of Health Resources, Inc.
He received an undergraduate degree from West Virginia University.”
$$$ UNVC $$$
$$$ UNVC $$$
CBD oil in the making! pic.twitter.com/IlSdP2yNZz
— Eric I Mitchell MD FACPE (@drheartbeat7) July 27, 2019
Per Dr. Mitchell:
UNVC is on the move. Timing is everything!!
— Eric I Mitchell MD FACPE (@drheartbeat7) July 25, 2019
You are correct. If a retail investor holds an otc stick in a margin account, the market makers can short that retail investors stock but the retail shareholder that owns that very stock can not short it. That’s why any long investor should not hold their UNVC shares in a margin account.
$$$ UNVC $$$
You must be referring to yourself?
$$$ UNVC $$$
If you are not a multi-millionaire, then this may be your opportunity.
Everyone should be able to invest on a equal playing field. High net worth individuals, market makers negative flippers, those of little or no integrity . But more important the everyday ordinary person that buys even one share of stock.
— Dr. David Dalton (@DrDavidDalton1) July 24, 2019
Post market-Premarket
Book it
If you are not a multi-millionaire, then this may be your opportunity.
Everyone should be able to invest on a equal playing field. High net worth individuals, market makers negative flippers, those of little or no integrity . But more important the everyday ordinary person that buys even one share of stock.
— Dr. David Dalton (@DrDavidDalton1) July 24, 2019
Post market-Premarket
Book it
I looked back on your post from a little while back that I am replying to so those on this board can see that you are legit and I quoted it:
“Fda approval for factory with Catalent partner is in last step. PTSD sleep medicine pain and opioid all prescription soon to be approve. Millionaire club begin very soon lads.
MJ”
We are there Mj! Your timeline has been slightly delayed but very accurate it seems.
$$$ UNVC $$$
If UNVC products are now clinically proven, does this mean the FDA has made this determination?
https://clinicaltrials.gov/ct2/about-studies/learn#WhoConducts
What Is a Clinical Study?
A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. ClinicalTrials.gov includes both interventional and observational studies.
Clinical Trials
In a clinical trial, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or changes to participants' behavior, such as diet. Clinical trials may compare a new medical approach to a standard one that is already available, to a placebo that contains no active ingredients, or to no intervention. Some clinical trials compare interventions that are already available to each other. When a new product or approach is being studied, it is not usually known whether it will be helpful, harmful, or no different than available alternatives (including no intervention). The investigators try to determine the safety and efficacy of the intervention by measuring certain outcomes in the participants. For example, investigators may give a drug or treatment to participants who have high blood pressure to see whether their blood pressure decreases.
Clinical trials used in drug development are sometimes described by phase. These phases are defined by the Food and Drug Administration (FDA).
Some people who are not eligible to participate in a clinical trial may be able to get experimental drugs or devices outside of a clinical trial through expanded access. See more information on expanded access from the FDA.
Observational Studies
In an observational study, investigators assess health outcomes in groups of participants according to a research plan or protocol. Participants may receive interventions (which can include medical products such as drugs or devices) or procedures as part of their routine medical care, but participants are not assigned to specific interventions by the investigator (as in a clinical trial). For example, investigators may observe a group of older adults to learn more about the effects of different lifestyles on cardiac health.
TO TOP
Who Conducts Clinical Studies?
Every clinical study is led by a principal investigator, who is often a medical doctor. Clinical studies also have a research team that may include doctors, nurses, social workers, and other health care professionals.
Clinical studies can be sponsored, or funded, by pharmaceutical companies, academic medical centers, voluntary groups, and other organizations, in addition to Federal agencies such as the National Institutes of Health, the U.S. Department of Defense, and the U.S. Department of Veterans Affairs. Doctors, other health care providers, and other individuals can also sponsor clinical research.
TO TOP
Where Are Clinical Studies Conducted?
Clinical studies can take place in many locations, including hospitals, universities, doctors' offices, and community clinics. The location depends on who is conducting the study.
TO TOP
How Long Do Clinical Studies Last?
The length of a clinical study varies, depending on what is being studied. Participants are told how long the study will last before they enroll.
TO TOP
Reasons for Conducting Clinical Studies
In general, clinical studies are designed to add to medical knowledge related to the treatment, diagnosis, and prevention of diseases or conditions. Some common reasons for conducting clinical studies include:
Evaluating one or more interventions (for example, drugs, medical devices, approaches to surgery or radiation therapy) for treating a disease, syndrome, or condition
Finding ways to prevent the initial development or recurrence of a disease or condition. These can include medicines, vaccines, or lifestyle changes, among other approaches.
Evaluating one or more interventions aimed at identifying or diagnosing a particular disease or condition
Examining methods for identifying a condition or the risk factors for that condition
Exploring and measuring ways to improve the comfort and quality of life through supportive care for people with a chronic illness
TO TOP
Participating in Clinical Studies
A clinical study is conducted according to a research plan known as the protocol. The protocol is designed to answer specific research questions and safeguard the health of participants. It contains the following information:
The reason for conducting the study
Who may participate in the study (the eligibility criteria)
The number of participants needed
The schedule of tests, procedures, or drugs and their dosages
The length of the study
What information will be gathered about the participants
Who Can Participate in a Clinical Study?
Clinical studies have standards outlining who can participate. These standards are called eligibility criteria and are listed in the protocol. Some research studies seek participants who have the illnesses or conditions that will be studied, other studies are looking for healthy participants, and some studies are limited to a predetermined group of people who are asked by researchers to enroll.
Eligibility. The factors that allow someone to participate in a clinical study are called inclusion criteria, and the factors that disqualify someone from participating are called exclusion criteria. They are based on characteristics such as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.
How Are Participants Protected?
Informed consent is a process used by researchers to provide potential and enrolled participants with information about a clinical study. This information helps people decide whether they want to enroll or continue to participate in the study. The informed consent process is intended to protect participants and should provide enough information for a person to understand the risks of, potential benefits of, and alternatives to the study. In addition to the informed consent document, the process may involve recruitment materials, verbal instructions, question-and-answer sessions, and activities to measure participant understanding. In general, a person must sign an informed consent document before joining a study to show that he or she was given information on the risks, potential benefits, and alternatives and that he or she understands it. Signing the document and providing consent is not a contract. Participants may withdraw from a study at any time, even if the study is not over. See the Questions to Ask section on this page for questions to ask a health care provider or researcher about participating in a clinical study.
Institutional review boards. Each federally supported or conducted clinical study and each study of a drug, biological product, or medical device regulated by FDA must be reviewed, approved, and monitored by an institutional review board (IRB). An IRB is made up of doctors, researchers, and members of the community. Its role is to make sure that the study is ethical and that the rights and welfare of participants are protected. This includes making sure that research risks are minimized and are reasonable in relation to any potential benefits, among other responsibilities. The IRB also reviews the informed consent document.
In addition to being monitored by an IRB, some clinical studies are also monitored by data monitoring committees (also called data safety and monitoring boards).
Various Federal agencies, including the Office of Human Subjects Research Protection and FDA, have the authority to determine whether sponsors of certain clinical studies are adequately protecting research participants.
Relationship to Usual Health Care
Typically, participants continue to see their usual health care providers while enrolled in a clinical study. While most clinical studies provide participants with medical products or interventions related to the illness or condition being studied, they do not provide extended or complete health care. By having his or her usual health care provider work with the research team, a participant can make sure that the study protocol will not conflict with other medications or treatments that he or she receives.
Considerations for Participation
Participating in a clinical study contributes to medical knowledge. The results of these studies can make a difference in the care of future patients by providing information about the benefits and risks of therapeutic, preventative, or diagnostic products or interventions.
Clinical trials provide the basis for the development and marketing of new drugs, biological products, and medical devices. Sometimes, the safety and the effectiveness of the experimental approach or use may not be fully known at the time of the trial. Some trials may provide participants with the prospect of receiving direct medical benefits, while others do not. Most trials involve some risk of harm or injury to the participant, although it may not be greater than the risks related to routine medical care or disease progression. (For trials approved by IRBs, the IRB has decided that the risks of participation have been minimized and are reasonable in relation to anticipated benefits.) Many trials require participants to undergo additional procedures, tests, and assessments based on the study protocol. These requirements will be described in the informed consent document. A potential participant should also discuss these issues with members of the research team and with his or her usual health care provider.
Questions to Ask
Anyone interested in participating in a clinical study should know as much as possible about the study and feel comfortable asking the research team questions about the study, the related procedures, and any expenses. The following questions may be helpful during such a discussion. Answers to some of these questions are provided in the informed consent document. Many of the questions are specific to clinical trials, but some also apply to observational studies.
What is being studied?
Why do researchers believe the intervention being tested might be effective? Why might it not be effective? Has it been tested before?
What are the possible interventions that I might receive during the trial?
How will it be determined which interventions I receive (for example, by chance)?
Who will know which intervention I receive during the trial? Will I know? Will members of the research team know?
How do the possible risks, side effects, and benefits of this trial compare with those of my current treatment?
What will I have to do?
What tests and procedures are involved?
How often will I have to visit the hospital or clinic?
Will hospitalization be required?
How long will the study last?
Who will pay for my participation?
Will I be reimbursed for other expenses?
What type of long-term follow-up care is part of this trial?
If I benefit from the intervention, will I be allowed to continue receiving it after the trial ends?
Will results of the study be provided to me?
Who will oversee my medical care while I am participating in the trial?
What are my options if I am injured during the study?
$$$ UNVC $$$
One more goal accomplished
— Dr. David Dalton (@DrDavidDalton1) July 23, 2019
“ Clinically Proven “
Sometimes to finish first is to be last. Univec Conglomerate Inc. Is the old Univec , but now an integrated powerful entity. It will take others years to duplicate. The Gold Standard
$$$ UNVC $$$
One more goal accomplished
— Dr. David Dalton (@DrDavidDalton1) July 23, 2019
“ Clinically Proven “
Sometimes to finish first is to be last. Univec Conglomerate Inc. Is the old Univec , but now an integrated powerful entity. It will take others years to duplicate. The Gold Standard
$$$ UNVC $$$
$$$ Univec Conglomerate $$$
http://prsync.com/smart-health/david-dalton-awarded-the-top--leaders-in-health-care-at-ifah-vegas--3082702/
David Dalton Awarded the “Top 100 Leaders in Health Care” at IFAH, Vegas 2019
IFAH - Friday, July 12, 2019.
Las Vegas, Nevada-- July 1, 2019 --David Dalton was conferred with the “Top 100 Leaders in Health Care” award for his significant contributions towards the health care sector at IFAH 2019, held at Caesars Palace, Vegas on June 18-20, 2019.
When asked about his vision for the company, David Dalton, Chairman, President, and CEO of Univec Inc., said,“The Univec Conglomerate today is a wholly integrated system where we have our own products, network of 70,000 pharmacies, CARF accredited mental health substance abuse clinics, virtual health care, wellness TellyDoc delivery system and it’s all tied into appropriate research so that we know what the outcome is. With our transdermal delivery patches, we have been able to verify that the reduction in Opioid prescribing has been over 25 percent as an alternative to the medication that is being prescribed today. We have been providing John Hopkins with medithadone for the last 15 years. When the farm bill was passed such the CBD can be given to the market place, they gave us a real opportunity for our transdermal delivery system and our Univec transdermal patch.”
Dr. David Dalton is both a pioneer and the forefront of an evolving pharmaceutical industry. He was the first pharmaceutical executive of African American origin in the chain drug industry and retired as a Corporate Vice President at Rite Aid Corporation. He has received honors from the President of the United States, the US Senate, and House of Representatives including the Senatorial Medal of Freedom. He is in three Halls of Fame including the West Virginia University School of Pharmacy Centennial Hall of Fame and is also one of the original members and directors of the National Council of Prescription Drug Programs (NCPDP).
IFAH 2019, a subsidiary of Prism Events, aims to bring together the brightest minds of the industry that have made significant contributions in the realm of health care. We offer a global platform which accolades the unparalleled efforts of health care professionals, medicine practitioners, fitness and wellness enthusiasts, and thought leaders. We are thrilled after the success of IFAH 2019, Las Vegas, and are looking forward to honoring the advancements in the health care domain.
For more details on IFAH Conference, Visit www.ifah.world
$$$ UNVC $$$
$$$ UNVC $$$
$$$ Univec Conglomerate $$$
http://prsync.com/smart-health/david-dalton-awarded-the-top--leaders-in-health-care-at-ifah-vegas--3082702/
David Dalton Awarded the “Top 100 Leaders in Health Care” at IFAH, Vegas 2019
IFAH - Friday, July 12, 2019.
Las Vegas, Nevada-- July 1, 2019 --David Dalton was conferred with the “Top 100 Leaders in Health Care” award for his significant contributions towards the health care sector at IFAH 2019, held at Caesars Palace, Vegas on June 18-20, 2019.
When asked about his vision for the company, David Dalton, Chairman, President, and CEO of Univec Inc., said,“The Univec Conglomerate today is a wholly integrated system where we have our own products, network of 70,000 pharmacies, CARF accredited mental health substance abuse clinics, virtual health care, wellness TellyDoc delivery system and it’s all tied into appropriate research so that we know what the outcome is. With our transdermal delivery patches, we have been able to verify that the reduction in Opioid prescribing has been over 25 percent as an alternative to the medication that is being prescribed today. We have been providing John Hopkins with medithadone for the last 15 years. When the farm bill was passed such the CBD can be given to the market place, they gave us a real opportunity for our transdermal delivery system and our Univec transdermal patch.”
Dr. David Dalton is both a pioneer and the forefront of an evolving pharmaceutical industry. He was the first pharmaceutical executive of African American origin in the chain drug industry and retired as a Corporate Vice President at Rite Aid Corporation. He has received honors from the President of the United States, the US Senate, and House of Representatives including the Senatorial Medal of Freedom. He is in three Halls of Fame including the West Virginia University School of Pharmacy Centennial Hall of Fame and is also one of the original members and directors of the National Council of Prescription Drug Programs (NCPDP).
IFAH 2019, a subsidiary of Prism Events, aims to bring together the brightest minds of the industry that have made significant contributions in the realm of health care. We offer a global platform which accolades the unparalleled efforts of health care professionals, medicine practitioners, fitness and wellness enthusiasts, and thought leaders. We are thrilled after the success of IFAH 2019, Las Vegas, and are looking forward to honoring the advancements in the health care domain.
For more details on IFAH Conference, Visit www.ifah.world
Whether you agree with Charles or not, he is a very high profile, well known individual and he clearly has interest in following Dr. Dalton just as we do.
$$$ UNVC $$$
“PPSI subsidiary of Univec Conglomerate Inc. (UNVC) will have patient assistance , access , a change is on it’s way.” - UNVC CEO Dr. David Dalton
https://www.linkedin.com/feed/update/urn:li:activity:6550158965915951104?commentUrn=urn%3Ali%3Acomment%3A%28activity%3A6550158965915951104%2C6550206489519276033%29
Charles Payne from Fox News is following UNVC CEO Dr. David Dalton on Twitter now.
$$$ UNVC $$$
He better or he’s fired too. Just kidding, I think his contract is up in a year or two.
I bought TRTC the week before Nevada went legal recreationally. 20,000 roughly at $0.20/share. Then they made the hair brain decision to do a reverse split. I now have 1333 shares and the pps is creeping closer to where I bought before the “necessary” split.
What did the reverse split accomplish? I hear people say it was totally necessary but they don’t specify why.
It sure didn’t do anything for the price per share and now I have fewer shares while Derek Peterson rewards himself with a fat check. He needs fired immediately for not doing his job.
I still can’t get over Derek Peterson having a guaranteed six figure income for the next three years when the company is using toxic death spiral financing and continually operates at a loss as well as investors. He’s a POS.
There is no question. Dr. Dalton’s Twitter and LinkedIn are his. Doc is going to change many lives.
LinkedIn:
https://www.linkedin.com/feed/update/urn:li:activity:6552612466923233280
Twitter:
Happy 4th of July pic.twitter.com/n3ayUjiCgc
— Dr. David Dalton (@DrDavidDalton1) July 4, 2019
It is very clear that we will have a website and products available for sale very soon, after UNVC CEO Dr. David Dalton provided clarification:
The Website is what I was referring to on my last tweet.
— Dr. David Dalton (@DrDavidDalton1) July 17, 2019
We will not make 30 day timeline
I believe your wish will come true.
unvc
That is huge and great info on our UNVC CEO David Dalton.
$$$ UNVC $$$
I am anxious to see that video from IFAH once it is released.
$$$ UNVC $$$
$$$ UNVC $$$ The #1 penny stick to buy right now:
Oh I think we will be there a lot sooner than that. Hopefully you will be happy for us longs.
$$$ UNVC $$$
It looks like the date of that picture was taken at around the time of the amended statement of ownership too.
$$$ ECOS $$$
Your “trading shares must no longer be in tact,” as described in the post that I am replying to.
$$$ UNVC $$$
I would say two out of the plethora you named are at $400 million per year. You know it too.
$$$ UNVC $$$
Listen to UNVC CEO Dr. David Dalton speak recently at the Hope Global Forum:
https://twitter.com/shortsleaves/status/1139131208183549952?s=21
$$$ UNVC $$$ The following was posted on SEDAR recently. You will see CEO Dr. David Dalton as well as UNVC referenced in it. This is part of the Univec Conglomerate.
https://sedar.com/CheckCode.do
REWARDSTREAM ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE INTEREST IN ISRAELI CANNABIS LICENSEE
Vancouver, British Columbia, June 12, 2019 – RewardStream Solutions Inc. (TSXV: REW and Frankfurt: JL4L, WKN Number A2APX1) (the “Company”) is pleased to announce it has entered into a definitive share purchase agreement (the “Definitive Agreement”), dated effective June 11, 2019, with EuroMed Therapeutics Ltd. (“EuroMed”) and its shareholders. EuroMed is an arms’-length company, established under the laws of the Province of British Columbia, for the purpose of cultivation and exporting of medical grade cannabis produced in greenhouse facilities located in Israel. EuroMed aims to be a leading low-cost high-quality medical grade cannabis producer in Israel with a focus on both the domestic Israeli market and the emerging European cannabis market. The Definitive Agreement replaces the existing letter of intent entered into with EuroMed and dated effective April 30, 2019.
EuroMed, through its participation in a joint venture, will embark on an industrial-scale cannabis farming operation including up to a 269,098 square foot (25 dunam) cannabis designated cultivation property located 45 minutes outside of Jerusalem, Israel. The venture intends to build a 22,000 square feet greenhouse facility on the property to cultivate medical grade cannabis for the purposes of servicing the domestic medical cannabis market and exports into Europe. EuroMed will be working with leading greenhouse engineering and construction firm Eisenberg Agri Company (Israel) Limited (EACi) to design and build a state-of-the-art modular greenhouse facility with expected completion by March 2020.
Further Details Regarding the Transaction
Pursuant to the Definitive Agreement, the Company proposes to acquire all of the outstanding share capital of EuroMed (the “Transaction”). In accordance with the terms of the Transaction, the Company proposes to consolidate its outstanding share capital (the “Share Consolidation”) on a two-for-one basis, and issue 40,000,000 post-Share Consolidation common shares (the “Consideration Shares”) to the shareholders of EuroMed in exchange for all of the outstanding share capital of EuroMed.
Prior to closing of the Transaction, the Company intends to apply to list its common shares on the Canadian Securities Exchange, and voluntarily delist its shares from the TSX Venture Exchange. On closing of the Transaction, it is anticipated that the Company will change its name to “EuroMed Therapeutics Ltd.”
In connection with the Transaction, the Company anticipates issuing 4,500,000 post-Share Consolidation common shares to an arms’-length third party who assisted in introducing the Transaction to the Company.
It is a condition to completion of the Transaction that the Company undertake a non-brokered private placement (the “Financing”) of subscription receipts (each, a “Receipt”) to raise not less than $2,500,000. In order to satisfy this condition, the Company intends to offer up to 5,000,000 Receipts, at a price of $0.50 per Receipt. Proceeds of the Financing will be held in escrow pending completion of the Transaction. Immediately prior to completion of the Transaction, each Receipt will automatically be converted into one unit of the Company (each, a “Receipt Unit”). Each “Receipt Unit” will consist of one post-Share Consolidation common share of the Company, and one-half-of- one share purchase warrant (each whole warrant, a “Receipt Warrant”). Each “Receipt Warrant” will entitle the holder to acquire an additional post-Share Consolidation common share at a price of $1.00 for a period of twenty-four months from their date of issue.
All securities issued in connection with the Financing, as well as the securities issued as compensation for introducing the Transaction, will be subject to a four-month-and-one-day statutory hold period.
Completion of the Transaction remains subject to a number of conditions, including receipt of any required regulatory and third-party consents, approval of minority shareholders of the Company to the delisting of the Company’s common shares from the TSX Venture Exchange, completion of the Share Consolidation, completion of the Financing, the Canadian Securities Exchange having conditionally accepted the listing of the Company’s common shares, the TSX
Venture Exchange having consented to the voluntarily delisting of the Company’s common shares, and the satisfaction of other customary closing conditions.
The Transaction cannot close until the required approvals are obtained, and the Company’s common shares have been delisted from the TSX Venture Exchange. There can be no assurance that the Transaction will be completed as proposed or at all, or that the Company’s common shares will be listed and posted for trading on any stock exchange. Trading in the Company’s common shares is currently suspended and it is anticipated that trading will remain suspended until completion of the Transaction.
Proposed Management and Board of Directors of the Resulting Issuer
Following completion of the Transaction, it is anticipated that the board of directors of the Company will be reconstituted to consist of Patrick Morris, Geoff Balderson, David Dalton and one additional nominee to be agreed between the Company and EuroMed. Management of the Company will consist of Patrick Morris as Chief Executive Officer and Corporate Secretary, and Geoff Balderson as Chief Financial Officer. The following are brief profiles of the proposed members of management and the board of directors:
Patrick Morris: Director, Chief Executive Officer and Corporate Secretary
Mr. Morris is an entrepreneur and capital markets executive experienced in a number of industries including resource exploration, pharmaceutical cannabis, blockchain technologies, and finance. With 15 years of capital markets experience raising funds for microcap companies and executing corporate development strategies, Mr. Morris has taken numerous companies public through initial public offerings and reverse takeover transactions. Mr. Morris also co-created and co-produced Canada’s first nationally syndicated radio show about growth stock opportunities broadcast on fourteen of the top-rated news talk stations across Canada.
Geoff Balderson: Director and Chief Financial Officer
Mr. Balderson is the President of Flow Capital Corp. and Harmony Corporate Services Ltd., both private business consulting companies located in Vancouver, British Columbia. Mr. Balderson has been an officer and director of several TSX Venture Exchange listed companies over the past 12 years. Prior to that he was an investment advisor at Union Securities and Georgia Pacific Securities Corp.
David Dalton: Independent Director
Dr. Dalton is a director of AGRIMED, which owns one of the twelve licenses authorized by the Commonwealth of Pennsylvania to grow and process medical cannabis. In addition to over 45 years’ experience in the pharmaceutical world, Dr. Dalton served over 18 years as Vice President of Rite Aid, a chain of retail drug stores, and then founded and served as Chairman, President, CEO of several successful pharmaceutical and pharmaceutical related companies: Mednet, ManagedcareRx, Sivault Systems. Dr. Dalton is presently Chairman, President, CEO of Wellness Teladoc, Pharmacy Services Inc, Health Resources Inc and Univec Inc (UNVC). Dr. Dalton is an inductee of three Halls of Fame, has received recognition from several presidents of the United States, and is a recipient of the Senatorial-Medal of Freedom. Dr. Dalton received a Doctor of Pharmacy from West Virginia University School of Pharmacy. In addition to his extensive background in pharmaceutical field, he is a visiting professor and lectures at several schools of pharmacy throughout the United States, and former President of West Virginia University School of Pharmacy Presidential Committee.
Further information regarding the Transaction, including a detailed use of proceeds for the Financing and financial information of EuroMed, will be made available in due course. Readers are encouraged to review the listing statement which will be prepared by the Company in connection with the listing of the Company on the Canadian Securities Exchange, and which will be made available under the Company’s profile on SEDAR (www.sedar.com).
$$$ UNVC $$$
Was my statement on revs false?
The shares are owned by longs. The shares are now slim pickings.
$$$ UNVC $$$
Harvest is at $6/share UNVC will be well beyond that.
Harvest Health has $57 million in revenues and we have at a bare minimum of $400 million in revenues with our two subs:
HRVSF $6.02 (-1.13%) on Yahoo Finance https://finance.yahoo.com/quote/HRVSF?p=HRVSF
$$$ UNVC $$$
When UNVC goes current, we are going to show two subsidiaries in the one company roll up that are generating at least $200 million revenues per year if not more. That is just the tip of the iceberg.
A unbelievable schedule .People get on board a express train getting ready to leave. Longs a rainbow Negative Toxic Sorry -short terms sorry. This is Univec Inc. Now Univec Conglomerate Inc . One company your CEO - Dr. David Dalton and Yes this is my account Unvc Book it
— Dr. David Dalton (@DrDavidDalton1) July 7, 2019
Happy 4th of July pic.twitter.com/n3ayUjiCgc
— Dr. David Dalton (@DrDavidDalton1) July 4, 2019
Black Enterprise BE100
— Dr. David Dalton (@DrDavidDalton1) June 29, 2019
Connect the Dot
I think the float seems pretty locked up too just as you do.
$$$ UNVC $$$